• English
  • 简体中文
Login Register
Current Location: Home > Drug Registration and Acceptance subscription Help
-
-
-
Visualized Analysis Export Evaluation Conclusion Evaluation Progress
Acceptance No. Drug Name Active Ingredient Dosage Form Classification Submission Acceptance Date Manufacturers Manufacturers Review Status Status Date View
JYSB2400080 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2024-04-08 Lilly France;Eli Lilly Nederland BV view
JYSB2101113 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2021-08-26 Sanofi-Aventis Deutschland GmbH view
JXSS2101025 甘精胰岛素利司那肽注射液2:1 insulin glargine;lixisenatide Injection Biological Products(3.1) Import Drug Application 2021-09-30 Sanofi-Aventis Groupe;Sanofi-Aventis Deutschland GmbH;Sanofi (China) Investment Co Ltd view
JYSB2400174 甘精胰岛素利司那肽注射液(Ⅱ) insulin glargine;lixisenatide Injection Biological Products Supplementary Application 2024-08-09 Sanofi-Aventis Deutschland GmbH;Sanofi Winthrop Industrie view
JYSZ2300013 甘精胰岛素注射液 insulin glargine Injection Biological Products License Renew 2023-02-28 Sanofi-Aventis Deutschland GmbH;Sanofi (China) Investment Co Ltd view
CXSL2500306 甘精胰岛素注射液 insulin glargine Injection Biological Products(3.3) New Drug Application 2025-04-16 Yifan Pharmaceutical (Shanghai) Co Ltd view
CXSB2101014 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2021-05-21 Gan & Lee Pharmaceuticals view
CYSB2500008 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2025-01-09 Gan & Lee Pharmaceuticals view
CYSB2300211 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2023-11-22 Sanofi (Beijing) Pharmaceuticals Co Ltd view
JXSL2101132 甘精胰岛素利司那肽注射液2:1 insulin glargine;lixisenatide Injection Biological Products(3.1) Import Drug Application 2021-11-17 Sanofi-Aventis Groupe;Sanofi (China) Investment Co Ltd view
CYSB2400141 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2024-06-01 Gan & Lee Pharmaceuticals view
JXSL2101131 甘精胰岛素利司那肽注射液1:1 insulin glargine;lixisenatide Injection Biological Products(3.1) Import Drug Application 2021-11-17 Sanofi KK;Sanofi (China) Investment Co Ltd view
CYSB2101082 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2021-06-03 Sanofi (Beijing) Pharmaceuticals Co Ltd view
CYSB2400236 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2024-09-13 Zhuhai United Laboratories Co Ltd view
CYSB2300082 甘精胰岛素注射液 insulin glargine Injection Biological Products(3.4) Supplementary Application 2023-04-13 Shandong New Time Pharmaceutical Co Ltd view
JTS2200006 OA-Arg-甘精胰岛素 Active ingredient Biological Products Disposable Import Drug Application 2022-02-18 Sanofi-Aventis Deutschland GmbH;Sanofi (China) Investment Co Ltd view
JYSB2400173 甘精胰岛素利司那肽注射液(Ⅰ) insulin glargine;lixisenatide Injection Biological Products Supplementary Application 2024-08-09 Sanofi KK;Sanofi-Aventis Deutschland GmbH view
JXSS2200042 甘精胰岛素注射液 insulin glargine Injection Biological Products(3.3) Import Drug Application 2022-12-27 Lilly France;Eli Lilly Nederland BV;Lilly Suzhou Pharmaceutical Co Ltd view
JYSB2101083 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2021-07-08 Sanofi-Aventis Deutschland GmbH view
CYSB2400321 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2024-12-11 Gan & Lee Pharmaceuticals;Gan&Lee Pharmaceuticals Shandong Co Ltd view